December 2017 Investor Update Presentation Visuals
Click on image above or here to download presentation visuals for December 2017 investor update. (2MB pdf)
Imagion Biosystems Launches New PEG-Coated Iron-Oxide Nanoparticles for Life Science Research Applications
Slow rate of clearance makes new product ideal for magnetic particle imaging. Imagion Biosystems Limited (ASX:IBX), a company dedicated to improving healthcare…
Investor Conference Call
Imagion Biosystems Limited (Imagion, ASX:IBX) invites shareholders and other interested parties to join CEO Robert Proulx for an update on the company's…
Appendix 4C for Q3 2017
In accord with ASX requirements, Imagion Biosystems has lodged "Appendix 4C, Quarterly report for entities subject to Listing Rule 4.7B" for the Quarter ended…
Investor Update — Corporate Presentation Visuals
Imagion Biosystems has updated investors by lodging the latest version of its corporate presentation visuals with the Australian Securities Exchange. Content…
Imagion Biosystems Secures Nanoparticle Manufacturer
Imagion Biosystems Limited (Imagion, ASX:IBX) has entered into a Master Service Agreement with ChemConnection BV, a Dutch contract manufacturing organization…
Pre-clinical Data Presented at the 2017 World Medical Imaging Congress Move MagSense® Closer to the Clinic
"Specific Detection of HER-2 positive tumors in mice using superparamagnetic relaxometry" is the title of a poster presented by Erika Vreeland, PhD, at the…
New mPEG-coated Nanoparticles Clear Slowly from Blood Circulation
At the April 2017 Annual Meeting of the American Association for Cancer Research, we first reported our long-circulating mPEG-coated PrecisionMRX®…
Magnetic Relaxometry for Cancer Detection
In this second segment of Bob Proulx's presentation to investors at the 2016 NobleCon meeting, he answers the question of how magnetic relaxometry might be…
Introduction to Magnetic Relaxometry
This video (below) captures the opening minutes of CEO Bob Proulx's address to the 2016 NobleCon meeting, where he outlines the medical need for a new cancer…